Articles from Diasome

The OPTI-2 trial provides early clinical evidence that liver-targeted mealtime insulin may help decouple tight glucose control from hypoglycemia risk, a longstanding tradeoff in intensive insulin therapy that has persisted despite advances in monitoring and delivery technologies

Data from randomized, double-blind study in 226 adults to be presented as an oral abstract